LAG-3 checkpoint inhibitor (Shire/Symphogen)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameLAG-3 checkpoint inhibitor (Shire/Symphogen)
Drug Alias NameLAG-3 inhibitors (Baxalta/Symphogen)
ClassificationBiologics
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShireBaxalta IncorporatedSymphogen A/S
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A